Highlights from ASCO
June 5, 2023
Dr Claudio Cerchione summarised the educational session on the management of multiple myeloma in special patient populations, such as elderly and patients with renal failure.
From 2 June till 6 June 2023: HIGHLIGHTS FROM ASCO
Your direct line with Chicago
The American Society of Clinical Oncology (ASCO) 2023 brings together leading experts in the different fields of cancer from around the world. And, as usual, they gather together in Chicago, USA. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the support of:
Daily highlights
Project in the spotlight
Real-world outcomes of axi-cel
July 7, 2025
Dr Allison Winter presented at ICML 2025 data that highlight a collaboration between KITE and the CIBMTR data registry, examining the outcomes of axicabtagene ciloleucel (axi-cel) for the treatment of
Phase 2 TRANSCEND FL study
July 7, 2025
At ICML 2025 in Lugano, new data from the phase 2 TRANSCEND study for lisocabtagene maraleucel (liso-cel) CAR-T cell therapy for indolent lymphoma were communicated.
SWOG S1826 TRIAL
July 7, 2025
At the ICML meeting, the results from the S1826 study were discussed, which focused on patients with advanced-stage Hodgkin Lymphoma (HL). This randomised phase 3 study compared brentuximab vedotin plus
Tafasitamab + lenalidomide in R/R DLBCL
July 4, 2025
During this ICML, Dr Bailly and Dr Johannes Düll had an interesting discussion around the combination of tafasitamab and lenalidomide, an FDA and EMA-approved treatment for relapsed or refractory diffuse
Bendamustine as Lymphodepleting Chemotherapy Prior to Axicabtagene Ciloleucel for the Treatment of Relapsed / Refractory Large B-Cell Lymphoma
July 3, 2025
Dr Alaa Ali presents an analysis from the CIBMTR registry, comparing the real-world safety and effectiveness of single-agent bendamustine versus standard fludarabine/cyclophosphamide (Flu/Cy) as lymphodepleting chemotherapy (LDC) before axicabtagene ciloleucel
SEQUOIA 5-year follow-up in Arm C
July 2, 2025
At ICML Lugano, Prof Dr Shadman presented updated results from SEQUOIA ARM C cohort, in patients with del(17p) after approximately 5 years of follow-up.
The MIDAS trial: MRD guided therapy for newly-diagnosed multiple myeloma
June 23, 2025
At EHA 2025, early results of the MRD-driven consolidation phase of the trial were presented. In this video, Prof Claudio Cerchione explains why MRD-driven treatment strategies like the one evaluated
The RESTORE trial: elritercept alone or in combination with ruxolitinib for the treatment of myelofibrosis
June 20, 2025
During EHA 2025, Prof Timothy Devos presented results of the ongoing, phase II RESTORE trial in which the activin receptor type IIA ligand trap elritercept is being evaluated in the
In-depth stories
Real-world outcomes of axi-cel
July 7, 2025
Dr Allison Winter presented at ICML 2025 data that highlight a collaboration between KITE and the CIBMTR data registry, examining the outcomes of axicabtagene ciloleucel (axi-cel) for the treatment of
Phase 2 TRANSCEND FL study
July 7, 2025
At ICML 2025 in Lugano, new data from the phase 2 TRANSCEND study for lisocabtagene maraleucel (liso-cel) CAR-T cell therapy for indolent lymphoma were communicated.
SWOG S1826 TRIAL
July 7, 2025
At the ICML meeting, the results from the S1826 study were discussed, which focused on patients with advanced-stage Hodgkin Lymphoma (HL). This randomised phase 3 study compared brentuximab vedotin plus
Tafasitamab + lenalidomide in R/R DLBCL
July 4, 2025
During this ICML, Dr Bailly and Dr Johannes Düll had an interesting discussion around the combination of tafasitamab and lenalidomide, an FDA and EMA-approved treatment for relapsed or refractory diffuse
Bendamustine as Lymphodepleting Chemotherapy Prior to Axicabtagene Ciloleucel for the Treatment of Relapsed / Refractory Large B-Cell Lymphoma
July 3, 2025
Dr Alaa Ali presents an analysis from the CIBMTR registry, comparing the real-world safety and effectiveness of single-agent bendamustine versus standard fludarabine/cyclophosphamide (Flu/Cy) as lymphodepleting chemotherapy (LDC) before axicabtagene ciloleucel
SEQUOIA 5-year follow-up in Arm C
July 2, 2025
At ICML Lugano, Prof Dr Shadman presented updated results from SEQUOIA ARM C cohort, in patients with del(17p) after approximately 5 years of follow-up.
The MIDAS trial: MRD guided therapy for newly-diagnosed multiple myeloma
June 23, 2025
At EHA 2025, early results of the MRD-driven consolidation phase of the trial were presented. In this video, Prof Claudio Cerchione explains why MRD-driven treatment strategies like the one evaluated
The RESTORE trial: elritercept alone or in combination with ruxolitinib for the treatment of myelofibrosis
June 20, 2025
During EHA 2025, Prof Timothy Devos presented results of the ongoing, phase II RESTORE trial in which the activin receptor type IIA ligand trap elritercept is being evaluated in the
Poster selection
Lisocabtagene maraleucel for 2nd line DLBCL: real-world data from the French DESCAR-T registry
July 8, 2025
During the 2025 ICML meeting, Dr Gabriel Brisou presented French real-world data of DLBCL patients treated with 2nd line liso-cel in the French DESCAR-T registry.
Axicabtagene Ciloleucel (axi-cel) in Relapsed/Refractory Central Nervous System Lymphoma (CNSL)
July 7, 2025
At ICML 2025, Prof Caron Jacobson presented a poster on a pilot study evaluating axicabtagene ciloleucel (axi-cel) in patients with primary and secondary CNS lymphoma, primarily in the second line
Real-world outcomes with brexucabtagene-autoleucel in R/R mantle cell lymphoma
July 7, 2025
During the 2025 ICML meeting, Prof Olalekan Oluwole shared the results of a systematic literature review and meta-analysis evaluating real-world outcomes for patients with relapsed/refractory mantle cell lymphoma (R/R MCL)
SEQUOIA – Results in Arm D
July 7, 2025
The SEQUOIA Arm D study explored the combination of zanubrutinib and venetoclax for untreated CLL/SLL patients, including those with abnormal TP53. Both normal and abnormal TP53 cohorts showed high response
Continuous zanubrutinib vs. fixed-duration VenO for newly diagnosed CLL
June 23, 2025
Prof Dr Talha Munir and colleagues performed an unanchored, matching-adjusted indirect comparison (MAIC) between continuous zanubrutinib and fixed duration VenO using data from SEQUOIA and CLL14.
Axicabtagene ciloleucel is cost-effective as 2nd line treatment for DLBCL
June 18, 2025
The results of the pivotal ZUMA-7 trial have convincingly established axicabtagene ciloleucel (axi-cel) as a preferred second line treatment for patients with large B-cell lymphoma (LBCL). More recently, data from
5-year ZUMA-3 – brexu-cel ALL
June 17, 2025
At EHA 2025, Prof Dr Olalekan Oluwole presented the 5-year follow-up data of this study. Patients in ZUMA-3 continued to experience a survival benefit with a 5-year overall survival (OS)
FYN::TRAF3IP2 fusion in PTCL-NOS
June 17, 2025
In a poster presented at EHA 2025 by Yilke Schoenmaekers, PhD student at the laboratory of experimental hematology of the KU Leuven, a mouse model was used to demonstrate how